Lastly, CAFs promote tumor progression by remodeling the ECM and producing cytokines and growth factors, e.g., IL-6 and stromal cell-derived factor-1 (SDF-1) [247–251], making them potential NP targets to improve immunotherapy efficacy [252]. This evidence concerns the gene CXCL12 and neoplasm.